European phase 3/3b experience with long-acting cabotegravir and rilpivirine: efficacy, safety and virologic outcomes

被引：0

作者：

Molina, J. -M. ^{[1
]}

Montes, M. L. ^{[2
]}

Esser, S. ^{[3
]}

De Castro, N. ^{[1
]}

Patel, P. ^{[4
]}

Dakhia, S. ^{[5
]}

Polli, J. W. ^{[4
]}

Garside, L. ^{[6
]}

D'Amico, R. ^{[4
]}

Talarico, C. ^{[4
]}

Van Eygen, V. ^{[7
]}

Vandermeulen, K. ^{[7
]}

Spreen, W. R. ^{[4
]}

Aboud, M. ^{[5
]}

Bosse, M. ^{[8
]}

机构：

[1] Univ Paris Diderot, St Louis Hosp, Infect Dis, Paris, France

[2] La Paz Univ Hosp, HIV Unit, Madrid, Spain

[3] Univ Hosp Duisburg Essen, Essen, Germany

[4] ViiV Healthcare, Res Triangle Pk, NC USA

[5] ViiV Healthcare, Brentford, England

[6] GlaxoSmithKline, London, England

[7] Janssen Res & Dev, Beerse, Belgium

[8] ViiV Healthcare, San Diego, CA USA

来源：

HIV MEDICINE | 2021年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

PE2/67

引用

页码：124 / 124

页数：1

共 50 条

[1] Efficacy and safety outcomes by BMI category over 48 weeks in phase 3/3b cabotegravir and rilpivirine long-acting trials
Elliot, E.
Polli, J.
Patel, P.
Garside, L.
Grove, R.
Barnett, V.
Roberts, J.
Ford, S.
Crauwels, H.
Birmingham, E.
D'Amico, R.
Baugh, B.
Bosse, M.
HIV MEDICINE, 2021, 22 : 32 - 32
[2] Efficacy and safety outcomes by BMI category over 48 weeks in Phase 3/3b cabotegravir and rilpivirine long-acting trials
Elliot, Emilie
Polli, Joseph
Patel, Parul
Garside, Louise
Grove, Richard
Barnett, Vincent
Roberts, Jeremy
Ford, Susan
Crauwels, Herta
Birmingham, Eileen
D'Amico, Ronald
Baugh, Bryan
Bosse, Matthew
HIV MEDICINE, 2022, 23 : 35 - 36
[3] Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96
Oka, Shinichi
Holohan, Vicki
Shirasaka, Takuma
Choi, Jun Yong
Kim, Yeon-Sook
Chamay, Nadine
Patel, Parul
Polli, Joseph W.
Ford, Susan L.
Crauwels, Herta
Garside, Louise
D'Amico, Ronald
Latham, Christine
van Solingen-Ristea, Rodica
Baugh, Bryan
van Wyk, Jean
HIV MEDICINE, 2024, 25 (03) : 381 - 390
[4] Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials
Elliot, Emilie R.
Polli, Joseph W.
Patel, Parul
Garside, Louise
Grove, Richard
Barnett, Vincent
Roberts, Jeremy
Byrapuneni, Sri
Crauwels, Herta
Ford, Susan L.
Van Solingen-Ristea, Rodica
Birmingham, Eileen
D'Amico, Ronald
Baugh, Bryan
van Wyk, Jean
JOURNAL OF INFECTIOUS DISEASES, 2024, 230 (01): : e34 - e42
[5] Efficacy, safety and implementation outcomes of Cabotegravir plus Rilpivirine long-acting by country in the Cabotegravir and rilpivirine implementation study in European locations (CARISEL)
Jonsson-Oldenbuettel, C.
Ghosn, J.
Sierra, J. Olalla
van der Valk, M.
Lutz, T.
Belkhir, L.
van Welzen, B. J.
Hove, K.
Ait-Khaled, M.
DeMoor, R.
Bontempo, G.
Latham, C. L.
Ngenzi, B.
Okoli, C.
Gutner, C. A.
Iyer, S.
Gill, M.
Czarnogorski, M.
D'Amico, R.
van Wyk, J.
HIV MEDICINE, 2023, 24 : 193 - 195
[6] Safety and effectiveness outcomes from the Carisel study: phase 3b hybrid-3 implementation study integrating cabotegravir plus rilpivirine long-acting into European clinical settings
Jonsson-Oldenbuettel, C.
Ghosn, J.
van der Valk, M.
Florence, E.
Vera, F.
Ait-Khaled, M.
Bontempo, G.
Latham, C.
Gutner, C. A.
Iyer, S.
DeMoor, R.
Gill, M.
Czarnogorski, M.
van Wyk, J.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 241 - 242
[7] Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir plus Rilpivirine Long-Acting Into European Clinical Settings
Jonsson-Oldenbuettel, Celia
Ghosn, Jade
van der Valk, Marc
Florence, Eric
Vera, Francisco
De Wit, Stephane
Rami, Agathe
Bonnet, Fabrice
Hocqueloux, Laurent
Hove, Kai
Ait-Khaled, Mounir
DeMoor, Rebecca
Bontempo, Gilda
Latham, Christine L.
Gutner, Cassidy A.
Iyer, Supriya
Gill, Martin
Czarnogorski, Maggie
D'Amico, Ronald
van Wyk, Jean
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (05) : 472 - 480
[8] WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS
Patel, P.
D'Amico, R.
Thiagarajah, S.
Wu, S.
Elliot, E.
Polli, J. W.
Upadhyay, O.
Van Solingen-Ristea, R.
Orkin, C.
Overton, E. T.
Swindells, S.
van Wyk, J.
Bosse, M.
Vannappagari, V.
Gray, L.
SEXUAL HEALTH, 2021, 18 (04) : VI - VI
[9] Efficacy and safety of long-acting intramuscular cabotegravir and rilpivirine in women: a substudy of the RELATIVITY cohort
Galindo Puerto, Maria Jose
Cabello Clotet, Noemi
Aldamiz-Echevarria Lois, Teresa
Llenas-Garcia, Jara
Mar Arcos, Mari
Troya, Jesus
Buzon Martin, Luis
Torralba, Miguel
Santacreu, Mireia
Aguilera Garcia, Maria
Cabello Ubeda, Alfonso
Crusells-Canales, Maria Jose
Morano, Luis
Pedrero Tome, Roberto
Martin Rico, Patricia
Montero Hernandez, Carmen
Perez Martinez, Desiree
de la Fuente Moral, Sara
Calderon Hernaiz, Ruth
Bernal, Enrique
Vivancos Gallego, Maria Jesus
Antonia Sepulveda, Maria
Cecilio, Alvaro
Arenas Garcia, Victor
Padilla, Sergio
Losa Garcia, Juan Emilio
de las Revillas Almajano, Francisco Arnaiz
Sanchez Guirao, Antonio Jesus
Garcia Navarro, Maria Del Mar
Cerezales Calvino, Ana
Garcinuno Jimenez, Maria Angeles
Ferreira Pasos, Eva Maria
Estebanez, Miriam
De la Calle Riaguas, Beatriz
Egido Murciano, Miguel
Ramos Vicente, Noemi
Clavero Olmos, Marta
Manuel Tiraboschi, Juan
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 75 - 76
[10] HIV virologic response and baseline genotypic resistance in a long-acting cabotegravir/rilpivirine initiation program
Masich, Anne M.
Gomes, Denese
Higginson, Robert T.
Morgan, Zara
Nixon, Daniel
Tran, Melissa
Winthrop, Elizabeth
Fulco, Patricia P.
AIDS, 2023, 37 (10) : 1641 - 1642

← 1 2 3 4 5 →